Table 2 Median percent change in biomarker levels from baseline by ACR-Pedi-30 responder status
Placebo +MTX | Infliximab 3 mg/kg +MTX | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
ACR-Pedi-30 Responder | ACR-Pedi-30 Nonresponder | P-value | ACR-Pedi-30 Responder | ACR-Pedi-30 Nonresponder | P-value | |||||
Biomarker | N | Median | N | Median | N | Median | N | Median | ||
Week 2 | ||||||||||
CRP | 29 | -11.1 | 28 | 0.0 | NS | 39 | -54.3 | 19 | 0.0 | NS |
ICAM-1 | 13 | -10.6 | 18 | 4.2 | NS | 21 | -24.5 | 9 | -3.8 | 0.0105 |
IL-12p40 | 16 | -16.6 | 16 | -16.2 | NS | 20 | -9.8 | 9 | -5.0 | NS |
IL-6 | 12 | -49.6 | 12 | 6.8 | 0.0334 | 17 | -57.1 | 9 | -66.1 | NS |
MMP-3 | 11 | -0.6 | 16 | -0.8 | NS | 21 | -60.3 | 9 | -4.8 | 0.0253 |
TNF-α | 16 | 0.0 | 18 | 0.0 | NS | 24 | 0.0 | 9 | 0.0 | NS |
VEGF | 12 | 4.6 | 18 | -5.6 | NS | 22 | -10.6 | 8 | -2.5 | NS |
Week 14 | ||||||||||
CRP | 29 | -40.0 | 27 | -6.3 | NS | 39 | -55.0 | 19 | 0.0 | 0.0011 |
ICAM-1 | 13 | -8.0 | 18 | 12.4 | NS | 22 | -21.7 | 8 | 4.8 | 0.0304 |
IL-12p40 | 15 | -19.4 | 17 | -18.5 | NS | 21 | -4.0 | 9 | 10.8 | NS |
IL-6 | 11 | -16.2 | 14 | -20.6 | NS | 18 | -62.6 | 8 | -26.5 | NS |
MMP-3 | 11 | 21.7 | 17 | -21.7 | NS | 22 | -55.5 | 8 | 8.2 | 0.0091 |
TNF-α | 16 | -4.8 | 18 | 0.0 | NS | 24 | 0.0 | 9 | 0.0 | NS |
VEGF | 11 | 13.2 | 18 | -6.7 | NS | 23 | -18.9 | 7 | 18.7 | NS |